Dalteparin Sodium

Summary

Dalteparin Sodium (CHEMBL1201460) is an approved oligosaccharide (ATC B01AB04) targeting SERPINC1; indicated across 24 conditions including venous thromboembolism and thrombotic disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Oligosaccharide
• ATC class: B01AB04
• Targets: 1 (SERPINC1)
• Indications: 24 conditions
• Clinical trials: 60

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201460
Name	Dalteparin Sodium
Type	Oligosaccharide
Max phase	4
ATC	B01AB04

Also known as: .alpha.-heparin, B01AB04, Boxol, Dalteparin, Dalteparin sodium, Dalteparina de sodio, Dalteparine sodique, FR-860, Fragmin, Fragmine, HEPARIN FRAGMENT KABI 2165, KABI-2165

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
SERPINC1	serpin family C member 1	Activation		0%	P01008

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): SERPINC1.

Top Reactome pathways

12 total, by targets touching each:

Pathway	Targets	Genes
Hemostasis	1	SERPINC1
R-HSA-140837	1	SERPINC1
R-HSA-140875	1	SERPINC1
R-HSA-140877	1	SERPINC1
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	1	SERPINC1
Metabolism of proteins	1	SERPINC1
Post-translational protein modification	1	SERPINC1
Post-translational protein phosphorylation	1	SERPINC1
Fibrin formation	1	SERPINC1
Initiation of coagulation cascade	1	SERPINC1
Regulation of clotting cascade	1	SERPINC1
Amplification and propagation of coagulation cascade	1	SERPINC1

Dominant GO biological processes

GO term	Targets
blood coagulation	1
regulation of blood coagulation	1
hemostasis	1

Indications & clinical

Indications

24 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
venous thromboembolism	4	MONDO:0005399	EFO:0004286
thrombotic disease	4	MONDO:0000831	HP:0004419
stroke disorder	3	MONDO:0005098	EFO:0000712
habitual spontaneous abortion	3	MONDO:0006774	EFO:1000954
thrombophilia	3	MONDO:0002305	EFO:0009315
exocrine pancreatic carcinoma	3	MONDO:0005192	EFO:0002618
breast neoplasm	3	MONDO:0021100	MONDO:0007254
lung neoplasm	3	MONDO:0021117	MONDO:0008903
hepatic veno-occlusive disease	3	MONDO:0019514	MONDO:0019514
brain injury	3	MONDO:0043510	MONDO:0043510
colorectal neoplasm	3	MONDO:0005335	MONDO:0005575
chronic kidney disease	3	MONDO:0005300	MONDO:0024327
toxic shock syndrome	2	MONDO:0001881	EFO:0006834
plasma cell myeloma	2	MONDO:0009693	EFO:0001378
central nervous system neoplasm	2	MONDO:0006130	EFO:1000158
ovarian cancer	2	MONDO:0008170	MONDO:0008170
sickle cell disease	2	MONDO:0011382	MONDO:0011382
renal cell carcinoma	1	MONDO:0005086	EFO:0000681

6 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 60.

Phase distribution

Phase	Trials
PHASE3	17
PHASE4	15
PHASE2	13
Not specified	9
PHASE2/PHASE3	3
PHASE1/PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05245877	PHASE4	RECRUITING	Pre- Vs. Postoperative Thromboprophylaxis in Pancreatic Surgery
NCT05255003	PHASE4	RECRUITING	STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis
NCT05735639	PHASE4	RECRUITING	THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)
NCT00245856	PHASE4	COMPLETED	Treatment of Upper Extremity Deep-Vein Thrombosis
NCT00264381	PHASE4	COMPLETED	Management of Superficial Thrombophlebitis
NCT00437697	PHASE4	TERMINATED	Thromboprophylaxis in Critically Ill Patients
NCT00445328	PHASE4	TERMINATED	Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients
NCT00655122	PHASE4	TERMINATED	Prophylaxis In Venous Thromboembolism In Primary Care, A Pilot Study
NCT00942968	PHASE4	COMPLETED	Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
NCT00966277	PHASE4	COMPLETED	Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients
NCT01245998	PHASE4	COMPLETED	Efficacy of Low Molecular Weight Heparin in Superficial Vein Thrombosis
NCT01714297	PHASE4	COMPLETED	Preoperative Versus Postoperative Start With Thromboprophylaxis in THA (Total Hip Arthroplasty)
NCT01741506	PHASE4	COMPLETED	Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung Cancer
NCT02607111	PHASE4	COMPLETED	A New Anticoagulation Method Using Dalteparin in Quotidian and Nocturnal Home Hemodialysis Patients
NCT05067153	PHASE4	UNKNOWN	Thromboprophylaxis in Oesophageal Cancer Patients
NCT03559114	PHASE3	RECRUITING	PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury (PROTEST)
NCT06153394	PHASE3	NOT_YET_RECRUITING	Prolonged Hypercoagulability Following Major Liver Resection for Malignancy
NCT00003674	PHASE3	COMPLETED	Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
NCT00006083	PHASE3	COMPLETED	Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
NCT00031837	PHASE3	TERMINATED	Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
NCT00135876	PHASE3	COMPLETED	Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients
NCT00260988	PHASE2/PHASE3	COMPLETED	A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery
NCT00432796	PHASE3	UNKNOWN	PERIOP 2 - A Safety and Effectiveness of LMWH vs Placebo Bridging Therapy for Patients on Long Term Warfarin Requiring Temporary Interruption of Warfarin.
NCT00519805	PHASE3	UNKNOWN	Dalteparin in Preventing Blood Clots in Patients With Lung Cancer
NCT00662831	PHASE2/PHASE3	COMPLETED	Study Of The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients
NCT00765063	PHASE2/PHASE3	COMPLETED	The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients (A6301086)
NCT00786474	PHASE3	COMPLETED	Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)
NCT00876915	PHASE3	TERMINATED	A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients
NCT00967382	PHASE3	COMPLETED	TIPPS: Thrombophilia in Pregnancy Prophylaxis Study
NCT01274637	PHASE3	COMPLETED	PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot
NCT01879618	PHASE3	COMPLETED	Use Of Fragmin In Hemodialysis
NCT02073682	PHASE3	COMPLETED	Cancer Venous Thromboembolism (VTE)
NCT02585713	PHASE3	COMPLETED	Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
NCT03045406	PHASE3	COMPLETED	Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer
NCT05171075	PHASE3	TERMINATED	A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
NCT00028678	PHASE2	COMPLETED	Dalteparin and Radiation Therapy in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme
NCT00041782	PHASE2	TERMINATED	Outpatient Treatment Of Deep Venous Thrombosis Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients
NCT00216866	PHASE2	COMPLETED	The Catheter Study: Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis
NCT00239980	PHASE2	COMPLETED	Fragmin in Ovarian Cancer: Utility on Survival (FOCUS)
NCT00323011	PHASE2	TERMINATED	FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

2 molecules share ≥1 primary target. Top 2 by shared-target count:

Molecule	Source	Status	Shared targets
IDRAPARINUX	ChEMBL	Phase 3	SERPINC1
fondaparinux	PubChem	Approved	SERPINC1